Codexis and Nestlé Health Science enter new health partnership
Protein engineering company Codexis, Inc has recently partnered with Nestlé Health Science in a large number of projects, such as the development of enzyme, CDX-6114 and management of phenylketonuria (PKU), an orphan metabolic disorder.
The deal will see Codexis receive an upfront payment of $14 million and potential milestones and royalties depending on product success. Codexis’ technology enables the implementation of biocatalytic solutions to meet customer needs. Nestlé Health Science will also receive access to the CodeEvolver protein engineering platform as part of the agreement.
Codexis will be eligible to receive clinical development, approval and commercial milestone payments related to CDX-6114 as well as tiered royalties on product sales. However, the company will remain responsible for the clinical development costs.
Related stories
- Stryker sets its sights on Utah expansion
- Johnson & Johnson subsidiary is set to expand its manufacturing capabilities in Ireland
- GE Healthcare turns its focus on 3D printing and robotics
“This transaction validates our CodeEvolver protein engineering platform technology as a biotherapeutic discovery engine, and also highlights our ability to establish customized partnerships for unlocking the power of proteins with a growing list of the world’s great companies,” said John Nicols, Codexis President and Chief Executive Officer.
“Enzymes are key to healthy functioning. When enzymes are not present or not working properly there can be an impairment of a wide range of processes critical for human health,” commented Greg Behar, Chief Executive Officer of Nestlé Health Science.
“The partnership with Codexis strengthens our footprint in the enzyme field, a fast developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”
